Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRX-7EAT · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Therapy with placebo |
| MRX-7EAT | EXPERIMENTAL | Therapy with experimental drug |
| Name | Type | Description |
|---|---|---|
| MRX-7EAT | DRUG | Application of up to two patches for up to 7 days. |
| Placebo | DRUG | Application of up to two patches for up to 7 days. |
Main Inclusion Criteria: * Subject is 14 years of age or older (with assent according to state law). * Females of child bearing potential must have a negative pregnancy test. * Subject has a diagnosis of acute tendonitis or bursitis of one shoulder with the onset of the current episode 5 days and ≤...
MRX-7EAT is an investigational small molecule being developed for the treatment of acute tendonitis, a musculoskeletal condition. It is formulated as a topical patch and has been studied in patients with acute tendonitis and bursitis of the shoulder. The drug is currently in Phase 3 clinical development.
MRX-7EAT is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker symbol BWAY. BrainsWay is conducting clinical trials to evaluate the safety and efficacy of MRX-7EAT for the treatment of acute tendonitis.
MRX-7EAT is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, which studied the drug in patients with acute tendonitis and bursitis of the shoulder.
MRX-7EAT has been studied in one clinical trial with the identifier NCT01161615. This was a Phase 3, randomized, double-blind, placebo-controlled study titled 'MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder.' The trial enrolled 350 participants in the United States and has been completed.
MRX-7EAT is a topical patch that combines etodolac and lidocaine. Etodolac is a nonsteroidal anti-inflammatory drug that reduces inflammation and pain, while lidocaine is a local anesthetic that numbs the area. This combination is designed to provide targeted relief for acute tendonitis and bursitis.
MRX-7EAT is a formulation that contains etodolac and lidocaine, as indicated by the clinical trial title. It is a topical patch that delivers these two active ingredients. The drug is being developed specifically for the treatment of acute tendonitis and bursitis of the shoulder.